|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CDC34 |
 Gene summary |
| Basic gene Info. | Gene symbol | CDC34 |
| Gene name | cell division cycle 34 | |
| Synonyms | E2-CDC34|UBC3|UBCH3|UBE2R1 | |
| Cytomap | UCSC genome browser: 19p13.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004359.1, | |
| Description | cell division cycle 34 homologubiquitin carrier proteinubiquitin-conjugating enzyme E2 R1ubiquitin-conjugating enzyme E2-32 KDA complementingubiquitin-conjugating enzyme E2-CDC34ubiquitin-protein ligase R1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 116948 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000099804 | ||
| HPRD : 00306 | ||
| Vega : OTTHUMG00000180558 | ||
| Protein | UniProt: P49427 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CDC34 | |
| BioGPS: 997 | ||
| Pathway | NCI Pathway Interaction Database: CDC34 | |
| KEGG: CDC34 | ||
| REACTOME: CDC34 | ||
| Pathway Commons: CDC34 | ||
| Context | iHOP: CDC34 | |
| ligand binding site mutation search in PubMed: CDC34 | ||
| UCL Cancer Institute: CDC34 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000209 | protein polyubiquitination | 20347421 | GO:0016567 | protein ubiquitination | 10373550 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 10373550 | GO:0043951 | negative regulation of cAMP-mediated signaling | 10373550 | GO:0070936 | protein K48-linked ubiquitination | 20061386 |
| Top |
| Ligand binding site mutations for CDC34 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F58 | A60V | COAD | 1 | E26 | E26K | HNSC | 1 | Y148 | V146L | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CDC34 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | F58 | A60V | 0.22237353 | E26 | E26K | -0.77065307 | Y148 | V146L | -0.18162199 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CDC34 from PDB |
| Top |
| Differential gene expression and gene-gene network for CDC34 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CDC34 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CDC34 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CDC34 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | C | E26 F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | D | E26 F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | A | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | B | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | C | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | B | F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | A | F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | D | F58 Y148 |
| Top |
| Conservation information for LBS of CDC34 |
| Multiple alignments for P49427 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |